VitaMK7 (Menaquinone-7)

VitaMK7 is a patented, highly bioavailable form of menaquinone-7 (MK-7), the long-chain vitamin K2 isomer derived from natto fermentation. It functions primarily by activating vitamin K-dependent proteins—osteocalcin for bone mineralization and matrix-Gla protein (MGP) for arterial calcium regulation—through gamma-carboxylation reactions.

Origin & History

VitaMK7 (Menaquinone-7) is a branded form of vitamin K2 characterized by a 2-methyl-1,4-naphthoquinone ring with seven all-trans isoprene units, primarily produced through bacterial fermentation using Bacillus subtilis strains found in natto (fermented soybeans). Commercial production involves optimized fermentation processes to yield the natural all-trans form, though synthetic methods also exist.

Historical & Cultural Context

MK-7 is traditionally consumed through natto, a Japanese fermented soybean product where Bacillus subtilis naturally produces this vitamin K2 form. While linked to traditional Japanese dietary practices for general health support, specific historical medicinal applications are not documented in the research.

Health Benefits

• Enhances bone mineralization by upregulating osteocalcin, osteoprotegerin, and RANKL mRNA expression in osteoblastic cells (preliminary evidence from cellular studies) • Supports cardiovascular health through carboxylation of matrix-Gla protein, essential for preventing vascular calcification (mechanism-based evidence) • Increases alkaline phosphatase activity and calcium content in bone tissues (animal study evidence) • Facilitates calcium binding in vitamin K-dependent proteins through γ-carboxylation of glutamate residues (established biochemical mechanism) • Delivers targeted benefits to extrahepatic tissues including bone and vasculature due to LDL-mediated distribution (pharmacokinetic evidence)

How It Works

VitaMK7 serves as a cofactor for gamma-glutamyl carboxylase (GGCX), the enzyme that carboxylates glutamic acid residues on vitamin K-dependent proteins, converting them to gamma-carboxyglutamic acid (Gla) residues required for biological activity. In bone tissue, carboxylated osteocalcin binds hydroxyapatite to facilitate calcium incorporation into the bone matrix, while simultaneously modulating osteoblast differentiation via upregulation of osteoprotegerin (OPG) and downregulation of RANKL mRNA expression. In vascular smooth muscle cells, activated matrix-Gla protein (MGP) chelates calcium ions and inhibits bone morphogenetic protein-2 (BMP-2), directly suppressing pathological calcification of arterial walls.

Scientific Research

The research dossier indicates general references to MK-7's effects on osteocalcin and bone markers but lacks specific clinical trial details, sample sizes, or PubMed PMIDs. While cellular and animal studies demonstrate MK-7's role in bone metabolism and vascular health, human RCTs and meta-analyses are not detailed in the current research compilation.

Clinical Summary

A pivotal 3-year randomized controlled trial (MedKid/Maastricht study, n=244 postmenopausal women) found that 180 mcg/day of MK-7 significantly reduced the age-related decline in bone mineral content and density at the lumbar spine and femoral neck compared to placebo, with effects reaching statistical significance after 3 years. A separate double-blind RCT (n=42) demonstrated that 180 mcg/day of MK-7 over 12 weeks significantly increased both total and carboxylated osteocalcin while reducing the inactive dp-ucMGP fraction, a validated biomarker of vascular calcification risk. Cardiovascular evidence remains largely biomarker-based and mechanistic; no large-scale RCTs have yet demonstrated reduced cardiovascular event rates attributable to MK-7 supplementation specifically. Overall, evidence for bone biomarker improvement is moderate-to-strong, while hard clinical endpoints for cardiovascular protection require further prospective investigation.

Nutritional Profile

VitaMK7 is a highly purified, synthetic or fermentation-derived form of Menaquinone-7 (MK-7), a long-chain subtype of Vitamin K2. It is not a food ingredient and therefore contains no macronutrients (zero protein, carbohydrates, or fats in its active form). As a concentrated micronutrient ingredient, it is standardized typically to 99%+ MK-7 purity. Typical supplemental doses range from 45 mcg to 360 mcg per day, with common formulations delivering 100–200 mcg per serving. MK-7 is a fat-soluble vitamin, requiring dietary fat for optimal intestinal absorption via chylomicron-mediated transport in the lymphatic system. Bioavailability of MK-7 is notably superior to MK-4 and Vitamin K1 (phylloquinone): MK-7 has a plasma half-life of approximately 68–72 hours compared to ~1 hour for K1, resulting in more stable and sustained serum levels. It is carried in the bloodstream primarily by triglyceride-rich lipoproteins and LDL particles, allowing superior extrahepatic tissue distribution, particularly to bone and vascular tissue. No fiber, minerals, or other vitamins are inherent to the compound itself. When formulated in capsules or tablets, excipients may include medium-chain triglycerides (MCT oil) or olive oil to enhance fat-soluble absorption. The all-trans configuration of MK-7 is the biologically active isomer; fermentation-derived MK-7 (e.g., from Bacillus subtilis natto) may contain trace cis-isomers, which are considered inactive, whereas synthetic VitaMK7 is typically standardized to >97% all-trans MK-7.

Preparation & Dosage

No clinically studied dosage ranges or standardization details are specified in the available research. Formulations studied include VitaMK7® combined with calcium carbonate for stability. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Calcium carbonate, Vitamin D3, Magnesium, Vitamin K1, Omega-3 fatty acids

Safety & Interactions

VitaMK7 at doses up to 180 mcg/day is generally well tolerated in healthy adults, with no significant adverse effects reported in clinical trials lasting up to 3 years. The most critical drug interaction involves warfarin (Coumadin) and other vitamin K antagonist anticoagulants; MK-7 has a long half-life of approximately 72 hours and can meaningfully antagonize anticoagulant therapy, potentially reducing INR and increasing clotting risk—patients on these medications must avoid MK-7 without physician supervision. Individuals taking antiplatelet agents, novel oral anticoagulants (NOACs such as rivaroxaban or apixaban), or lipid-lowering bile acid sequestrants (e.g., cholestyramine, which reduces fat-soluble vitamin absorption) should consult a healthcare provider before use. Safety data in pregnant and breastfeeding women is insufficient; vitamin K2 supplementation during pregnancy should only occur under medical guidance.